The insider cluster is routine and non-informative. Director Wang's sales follow a derivative exercise and are small relative to market cap. Monitor for any 8-K filings that might explain the derivative exercise timing.
ONC drugs
ONC drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 11 $346.51entry
- T+1 · 2mo ago +2.11%α +2.56% · $353.83
- T+5 · 2mo ago +1.25%α +1.47% · $350.84
- T+20 · 6w ago +2.30%α +0.43% · $354.47
- T+46 · todayOpen
- T+60 · in 20d Pending
Price Chart
How similar events traded
Executive Summary
Director Wang Xiaodong executed a large derivative exercise and sold a substantial block of shares totaling ~$13.4M in open-market sales on September 8, 2026, while the Principal Accounting Officer sold a small routine position. The director's sales are significant in absolute dollar terms but represent a modest 0.03% of the $39.9B market cap, falling below the 0.1% materiality threshold. The derivative exercise (non-cash) and subsequent same-day sales suggest a planned liquidity event rather than a bearish signal, consistent with the historical pattern of insider selling at this company. The cluster is neutral, the dollar value is trivial relative to market cap and the director's sales follow a derivative exercise, not a conviction sell.
Key Financial Metrics
Key Facts
- Director Wang Xiaodong sold ~$13.4M in open-market sales on September 8, 2026, following a derivative exercise of 403,351 shares at $0 and 31,027 shares at $36.90.
- Principal Accounting Officer Ball Titus B. sold 132 shares for $47K on September 1, 2026, a routine, trivial position reduction.
- Total open-market sales of ~$13.4M represent only 0.03% of the $39.9B market cap, well below the 0.1% materiality threshold.
- The derivative exercise and same-day sales pattern suggests a planned liquidity/vesting event rather than an informed bearish view.
Financial Impact
Total open-market sales of ~$13.4M, or 0.03% of market cap, immaterial relative to company size.
Risk Factors
- Director Wang may continue selling post-exercise, creating modest overhang.
- The derivative exercise adds ~434K shares to the float, though this is negligible for a $39.9B company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ONC-1789074089062 |
Track record
27 reports on ONC
3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +12.55% at T+60 after the Aug 5, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $416.54 Now $411.29 −1.26% settles Nov 23
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $411.29 −2.07% settles Nov 18
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $411.29 −1.45% ▼ −1.45% +0.25% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $411.29 +1.06% ▲ +2.35% −0.24% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $387.25 to $415.96 Now $411.29 +6.21% ▲ +7.41% +4.12% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $411.29 +8.87% ▲ +11.17% +12.08% vs SPY
- Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $411.29 −13.73% ▲ +3.11% +3.53% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $411.29 +11.74% ▼ −0.76% +0.42% vs SPY
- Sep 10, 20269w ago Insider Cluster Neutral 3/10 Viewing Entry $346.51 to $350.84 Now $411.29 +18.69% ▲ +1.25% +1.47% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $411.29 +14.80% ▼ −1.24% −0.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers